Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.88 USD | -2.63% | -9.82% | +30.47% |
Apr. 25 | Immunome, Inc. Appoints Sandra M. Swain to Board of Directors | CI |
Apr. 15 | Guggenheim Starts Immunome With Buy Rating, $35 Price Target | MT |
Financials (USD)
Sales 2024 * | 8M | Sales 2025 * | - | Capitalization | 851M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -149M | EV / Sales 2024 * | 106 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.13
x | P/E ratio 2025 * |
-6
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
1 day | +1.40% | ||
1 week | -17.00% | ||
Current month | -42.22% | ||
1 month | -40.58% | ||
3 months | -13.05% | ||
6 months | +59.87% | ||
Current year | +33.27% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 64 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 13.97 | -2.04% | 668 420 |
24-04-25 | 14.26 | -0.07% | 737,149 |
24-04-24 | 14.27 | -2.66% | 555,483 |
24-04-23 | 14.66 | -4.06% | 891,857 |
24-04-22 | 15.28 | -1.29% | 1,315,586 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.27% | 851M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- IMNM Stock